相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名:
CAL-62
- 库存:
1x10^6/瓶/支
- 供应商:
上海酶研
- 肿瘤类型:
详询
- 细胞类型:
人甲状腺癌细胞
- ATCC Number:
详询
- 品系:
CAL-62
- 组织来源:
人甲状腺癌细胞
- 相关疾病:
CAL-62
- 物种来源:
哺乳动物
- 免疫类型:
详询
- 细胞形态:
贴壁/悬浮
- 是否是肿瘤细胞:
详询
- 器官来源:
人甲状腺癌细胞
- 运输方式:
顺丰快递
- 年限:
5年
- 生长状态:
生长良好
CAL-62/CAL-62细胞系/CAL-62细胞株/CAL-62人甲状腺癌细胞
Cell line name CAL-62
Synonyms Cal-62; CAL 62; Cal 62; CAL62; Centre Antoine Lacassagne-62
Accession CVCL_1112
Resource Identification Initiative To cite this cell line use: CAL-62 (RRID:CVCL_1112)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~24 hours (DSMZ=ACC-448).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
Mutation; HGNC; 2348; CREBBP; Simple; p.Glu1541Ter (c.4621G>T); Zygosity=Heterozygous (PubMed=30737244).
Mutation; HGNC; 3373; EP300; Simple; p.Asp1485fs (c.4454delA); Zygosity=Homozygous (PubMed=30737244).
Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Homozygous (PubMed=23833040; PubMed=30737244).
Mutation; HGNC; 7773; NF2; Simple; p.Glu215Ter (c.643G>T); Zygosity=Homozygous (PubMed=30737244).
Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Homozygous (PubMed=30737244).
Genome ancestry Source: PubMed=30894373
Origin % genome
African 0.55
Native American 0.27
East Asian, North 1.91
East Asian, South 0
South Asian 1.04
European, North 46.22
European, South 50.02
Disease Thyroid gland anaplastic carcinoma (NCIt: C3878)
Anaplastic thyroid carcinoma (ORDO: Orphanet_142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 70Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=906828; DSMZ=ACC-448; PubMed=18713817; PubMed=25365311; PubMed=30737244
Markers:
Amelogenin X
CSF1PO 9,12
D2S1338 19,23
D3S1358 16
D5S818 9,12
D7S820 10
D8S1179 13
D13S317 12
D16S539 12,13
D18S51 16
D19S433 14
D21S11 32.2
FGA 19
Penta D 13
Penta E 5,10
TH01 7,9
TPOX 8,9
vWA 16
Run an STR similarity search on this cell line
Publications
PubMed=1369551
Gioanni J., Zanghellini E., Mazeau C., Zhang D., Courdi A., Farges M.-F., Lambert J.-C., Duplay H., Schneider M.
Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland.
Bull. Cancer 78:1053-1062(1991)
PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)
PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., M, Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注:由上海酶研生物科技有限公司提供;
*发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.
技术资料






